Skip to main content
. 2020 Oct 28;11(10):926. doi: 10.1038/s41419-020-03108-2

Fig. 4. Effects of ZJQ-24 on the AKT/mTOR pathway in vivo and in vitro.

Fig. 4

A Expressions of mTORC1 and mTORC2 in clinical HCC samples. HCC samples (n = 20) were stained using antibodies to p-mTOR(Ser2448), Rictor, Raptor, and targets downstream of mTORC1 (p-4EBP1(Thr37/46), p-S6(Ser240/244)) and mTORC2 (p-Akt(Ser473)). B ZIQ-24 inhibited PI3K/AKT/mTOR signaling pathway proteins. C ZIQ-24 inhibited the expression of substrate of mTORC1. D ZIQ-24 inhibited the lipid kinases activity of mTORC. E ZJQ-24 inhibited the endogenous kinases activity of mTORC1. HepG2 and HUH-7 cells extracts were subjected to immunoprecipitation (IP) with pre-immune (IgG) or anti-Raptor. The immunoprecipitates were incubated with dephosphorylated GST–S6K1 in the presence of the indicated concentrations of ZJQ-24 or DMSO. F The expressions of VEGF, p-AKT (Ser473), p-mTOR (Ser2448), Raptor, Rictor, p-4EBP-1 (Thr37/46), and p-P70S6K (Thr389) were measured by immunohistochemistry with tumor tissues.